Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Nader Kabbani, who led the technology giant’s acquisition of PillPack and the launch of Amazon Pharmacy, will take the chief ...

Hims & Hers continues to deliver strong revenue growth. Meanwhile, the company surprised investors by offering a long-term ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Hims & Hers management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Read why HIMS ...

Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

A post-earnings rally in Hims & Hers Health Inc. has turned co-founder and Chief Executive Officer Andrew Dudum into a weight-loss billionaire.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...